Prognostic indicators of KRAS G12X mutations in pancreatic cancer.

被引：0

作者：

Ardalan, Bach

Ciner, Aaron

Baca, Yasmine

Darabi, Sourat

Kasi, Anup

Lou, Emil

Azqueta, Jose Ignacio

Xiu, Joanne

Nabhan, Chadi

Shields, Anthony Frank

Pishvaian, Michael J.

Korn, Wolfgang Michael

Goel, Sanjay

机构：

[1] Univ Miami, Miami, FL USA

[2] Univ Maryland, Baltimore, MD 21201 USA

[3] Caris Life Sci, Phoenix, AZ USA

[4] Hoag Family Canc Inst, Newport Beach, CA USA

[5] Univ Kansas Med Ctr, Westwood, KS USA

[6] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA

[7] Univ Miami, Sylvester Canc Ctr, Miami, FL USA

[8] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[9] Johns Hopkins Univ, Sch Med, Washington, DC USA

[10] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

735

引用

页码：735 / 735

页数：1

共 50 条

[1] Development and clinical validation of a universal KRAS G12X ddPCR assay for the molecular monitoring of pancreatic cancer patients
Hussung, S.
De Nard, B.
Unal, Y.
Pistoni, C.
Fritsch, R.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 15 - 15
[2] Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
Kirschner, Tonia
Mueller, Matthias P.
Rauh, Daniel
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (08) : 6044 - 6051
[3] KRAS G12X mutants display differential preferences in downstream effector binding
Ash, Leonard J.
Bourdain, Ottavia
Lam, Dennis
Pallas, Shlomo S.
Wolfe, Andrew L.
CANCER RESEARCH, 2024, 84 (06)
[4] Prognostic values of different subtypes of KRAS mutations in pancreatic cancer
Smirnov, S.
Subach, H.
Hutkouskaya, K.
Gremza, K.
Portyanko, A.
ANNALS OF ONCOLOGY, 2021, 32 : S1355 - S1356
[5] Genomic and prognostic differences in patients with different KRAS mutations in pancreatic cancer
Xu, C.
Wang, W.
Li, X.
Zeng, Y.
Pang, F.
ANNALS OF ONCOLOGY, 2023, 34 : S909 - S909
[6] Prognostic and predictive value of circulating KRAS mutations in stage IV pancreatic cancer
Hussung, S.
Follo, M.
Michalczyk, S.
Hajkova, A.
Fritsch, K.
Boerries, M.
von Bubnoff, N.
Scherer, F.
Duyster, J.
Fritsch, R.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 124 - 125
[7] Targeting KRAS G12C mutations in colorectal cancer
Zhao, Ming-He
Wu, Ai-Wen
GASTROENTEROLOGY REPORT, 2023, 11
[8] Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer.
Nissim, Sahar
Leshchiner, Ignaty
Mancias, Joseph
Greenblatt, Matthew
Maertens, Ophelia
Cassa, Christopher
Rosenfeld, Jill
Cox, Andrew
Hedgepeth, John
Wucherpfennig, Julia
Kim, Andrew
Henderson, Jake
Gonyo, Patrick
Brandt, Anthony
Lorimer, Ellen
Unger, Bethany
Getz, Gad
Sunyaev, Shamil
Harper, Wade
Cichowski, Karen
Kimmelman, Alec
Houvras, Yariv
Syngal, Sapna
Williams, Carol
Goessling, Wolfram
MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 30 - 31
[9] SIL-204 siRNA encapsulated in extended release microparticles for the treatment of localized cancer that harbors a KRAS G12x or G13D mutation.
Shirvan, Mitchell
Racheli, M.
Yaron, Michal
Zorde, Elina
Shragai, Orit
Maor Aloni, Revital
Bernstein, Adi
Shinar, Doron
Nyska, Abraham
Hadar, Ilan
Peled, Amnon
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 745 - 745
[10] Mechanisms of acquired resistance to KRAS G12C inhibition in cancer.
Awad, Mark
Liu, Shengwu
Arbour, Kathryn
Zhu, Viola
Johnson, Melissa
Heist, Rebecca
Patil, Tejas
Riely, Gregory
Jacobson, Joseph
Dilly, Julien
Yang, Xiaoping
Persky, Nicole
Root, David
Sholl, Lynette
Lim, Lee
Garg, Kavita
Li, Mark
Engstrom, Lars
Waters, Laura
Lawson, J. David
Olson, Peter
Christensen, James
Lito, Piro
Ou, Sai-Hong Inatius
Janne, Pasi
Aguirre, Andrew
CANCER RESEARCH, 2021, 81 (13)

← 1 2 3 4 5 →